Klinguer-Hamour Christine, Caussanel Véronique, Beck Alain
Centre d'immunologie Pierre Fabre, 5, avenue Napoléon III, BP 60497, 74160 Saint-Julien en Genevois, France.
Med Sci (Paris). 2009 Dec;25(12):1116-20. doi: 10.1051/medsci/200925121116.
Monoclonal antibodies (mAb) are attractive biologic drugs because of their specificity and well understood mechanisms of action. So far, most mAb have been developed for treating cancers or immunological disorders. However, the antibiotic resistance crisis, emerging viral diseases and bioterrorism have increased the development of anti-infectious mAb, for which more than twenty clinical trials are in progress to evaluate their safety and efficacy. The synergies obtained using combinations of anti-infectious mAb and small molecule drugs will certainly offer new opportunities for the treatment of infectious diseases.
单克隆抗体（mAb）因其特异性和作用机制明确而成为颇具吸引力的生物药物。到目前为止，大多数单克隆抗体已被开发用于治疗癌症或免疫紊乱。然而，抗生素耐药性危机、新出现的病毒性疾病和生物恐怖主义促使抗传染性单克隆抗体的研发增加，目前有二十多项临床试验正在进行，以评估其安全性和有效性。使用抗传染性单克隆抗体与小分子药物的组合所获得的协同作用必将为传染病治疗带来新机遇。
